Evidence map›Paper›PMID 39334542›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2024

Clearing the air: microcosting the carbon impact of drug-susceptible pulmonary TB treatment.

M F Martins, M R Dauphinais, A Tabackman, P B Narasimhan, M C Nielsen, N S Miller, A Sahay, M Namachivayam, S Janarthanan, C Palanivel and 3 more

Abstract read
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

M F MartinsBoston Medical Center, Boston, MA, USA;, Boston University School of Medicine, Boston, MA, USA.
M R DauphinaisBoston Medical Center, Boston, MA, USA.
A TabackmanBoston Medical Center, Boston, MA, USA;, Boston University School of Medicine, Boston, MA, USA.
P B NarasimhanJawaharlal Institute for Postgraduate Medical Education and Research, Puducherry, India.
M C NielsenBoston Medical Center, Boston, MA, USA;, Boston University School of Medicine, Boston, MA, USA.
N S MillerBoston Medical Center, Boston, MA, USA;, Boston University School of Medicine, Boston, MA, USA.
A SahayJohns Hopkins University, Baltimore, MD, USA.
M NamachivayamJawaharlal Institute for Postgraduate Medical Education and Research, Puducherry, India.
S JanarthananJawaharlal Institute for Postgraduate Medical Education and Research, Puducherry, India.
C PalanivelJawaharlal Institute for Postgraduate Medical Education and Research, Puducherry, India.
S LakshminarayananJawaharlal Institute for Postgraduate Medical Education and Research, Puducherry, India.
K G KouraInternational Union Against Tuberculosis and Lung Disease, Paris, France;, UMR261 MERIT, Université Paris Cité, IRD, F-75006, Paris, France.
P SinhaBoston Medical Center, Boston, MA, USA;, Boston University School of Medicine, Boston, MA, USA.

Funding

Nutritional Interventions to End Tuberculosis among Persons with HIV (NUTRIENT)K01AI167733 · NIAID · BOSTON MEDICAL CENTER · PI Pranay Sinha · 2023 to 2026
$512k
NIAID NIH HHS K01 AI167733
6 · The paper itself

Abstract

<sec><title>BACKGROUND</title>More than 10 million individuals develop active TB each year. The diagnosis and treatment of TB create greenhouse gas emissions, contributing to climate change. This study estimates the carbon footprint (CF) of successfully treating one person with drug-susceptible pulmonary TB (DS-PTB) in India.</sec><sec><title>METHODS</title>We defined the cascade of care for DS-PTB using national guidelines, interviews, and direct observation. We estimated the inputs for TB diagnosis and treatment in United States dollars, kilowatts per hour, and kilometres travelled; we converted them into carbon dioxide emissions equivalents (CO₂e) using an appropriate calculator.</sec><sec><title>RESULTS</title>The CF of diagnosing and treating one person with DS-PTB in India is 103.8 kg CO₂e: 31.9% attributable to diagnosis and 68.1% to treatment. Emissions came primarily from first-line drugs (21.2%), hospitalisations (17.4%), and laboratory processes.</sec><sec><title>CONCLUSION</title>We conservatively estimate that treating all persons with TB in India would produce at least 290,640 metric tonnes of CO₂e per year, approximately the same emissions as 63,182 passenger cars in the United States. It is evident that one of India's leading public health challenges also contributes meaningfully to climate change.</sec>.

Indexed as

Antitubercular AgentsCarbon FootprintTuberculosis, PulmonaryCarbon DioxideHumansIndiaAntitubercular AgentsCarbon Dioxide

Identifiers

PMID39334542
PMCPMC12313319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.